Answers are grounded in this paper and cite their sources.
Background: Insulin resistance (IR) is one feature of obese patients with type 2 diabetes and associated with a clustering of metabolic abnormalities. Obesity perse is one component of a cluster of metabolic abnormalities that included the hyperinsulinemia. Objectives: This study aims to assess the status of IR in obese nondiabetic subjects using HOME-IR index and demonstrate the therapeutic effect of metformin as an insulin sensitizer. Materials and Methods: A total number of 76 out of 97 obese male completed the study. The subjects assigned to receive a single-dose of metformin (850 mg/daily) for 3 months. Anthropometric measurements and the following biochemical tests were carried on before and after treatment: Fasting serum glucose, glycosylated hemoglobin, and fasting serum insulin. The basal metabolic rate (BMR), HOMA-IR, and insulin sensitivity (IS) were calculated using a specific formula. Results: Metformin therapy resulted in a significant decrease in body mass index of obese subjects. This effect is associated with significant decrease BMR. Significant decrease HOMA-IR observed in Classes I and II obesity (62.95% and 65.13%, respectively) and to a lesser extent in Class III (72.48%). Significant improvement in glycosylated hemoglobin was observed in Classes I and II obesity. HOMA-IR index is significantly correlated with glycosylated hemoglobin before and after treatment. Conclusions: Metformin improves IS in nondiabetic obese men besides its favorable effect in reducing the body weight.
No takes yet. Share an insight, caveat, or question.
Al-Nimer et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: